Date: 2014-04-29
Type of information: Capital increase
Company: Skyepharma (UK)
Investors:
Amount:
Funding type: capital increase
Planned used:
Others: * On April 29, 2014, Skyepharma has announced that following the passing of all resolutions at the General Meeting and the Bondholder Meeting, all the conditions relating to the Capital Raising of £112 million are now satisfied for Admission of the Group’s 58,684,614 New Ordinary Shares. Skyepharma has given notice that it intends to accept for purchase in full all valid tenders of its £60,822,124 6.5 per cent. Guaranteed Bonds due 2024 (the “Bonds”) representing approximately 99.67% of the outstanding Bonds, subject to certain conditions. In addition, it is expected that Skyepharma (Jersey) Limited will give notice on 30 April 2014 to redeem the remaining Bonds following such repurchase. Accordingly, the Bonds are expected to be redeemed in full on or around 2 May 2014. Following Admission, the number of ordinary shares that the Company will have in issue will be 104,812,259. The total number of voting rights of the Company will be 104,812,259.
Therapeutic area:
